Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | KDM5A | P29375 | 3/20 | 0.34 |
| ▸ | PHF8 | Q9UPP1 | 3/20 | 0.34 |
| ▸ | KDM2A | Q9Y2K7 | 3/20 | 0.34 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.34 |
| ▸ | KDM4A | O75164 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
| ▸ | NAAA | Q02083 | 2/20 | 0.31 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11798387 | 0.97 | — | — | |
| SCHEMBL5883811 | 0.95 | SIGMAR1 (0.56) | SIGMAR1CYP1A2KDM5APHF8KDM2A | |
| SCHEMBL7751427 | 0.95 | SIGMAR1 (0.56) | SIGMAR1CYP1A2KDM5APHF8KDM2A | |
| SCHEMBL7614811 | 0.92 | SIGMAR1 (0.60) | SIGMAR1CYP1A2KDM5APHF8KDM2A | |
| SCHEMBL7613945 | 0.92 | SIGMAR1 (0.60) | SIGMAR1CYP1A2KDM5APHF8KDM2A | |
| SCHEMBL11022414 | 0.92 | SIGMAR1 (0.60) | SIGMAR1CYP1A2KDM5APHF8KDM2A | |
| SCHEMBL7619522 | 0.92 | SIGMAR1 (0.60) | SIGMAR1CYP1A2KDM5APHF8KDM2A | |
| SCHEMBL7618517 | 0.92 | SIGMAR1 (0.60) | SIGMAR1CYP1A2KDM5APHF8KDM2A | |
| SCHEMBL7615078 | 0.92 | SIGMAR1 (0.60) | SIGMAR1CYP1A2KDM5APHF8KDM2A | |
| SCHEMBL7614743 | 0.92 | SIGMAR1 (0.60) | SIGMAR1CYP1A2KDM5APHF8KDM2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7091357-B2 | Chain-modified pyridino-N substituted nicotine compounds for use in the treatment of CNS pathologies | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2006-08-15 | — | — | US | disclosed |
| US-20030225142-A1 | Chain-modified pyridino-N substituted nicotine compounds for use in the treatment of CNS pathologies | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2003-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225142-A1 | Chain-modified pyridino-N substituted nicotine compounds for use in the treatment of CNS pathologies | CHRNA4, CHRNA2, CHRNA5 | SIGMAR1 152/4885CYP1A2 744/4885KDM5A 2241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.